Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

1.785 +0.365 (+25.70%)
Streaming Delayed Price Updated: 11:28 AM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate
The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) ADX-2191 to treat retinitis pigmentosa (RP). ADX-2191 is a... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers BeyondSpring (NASDAQ:BYSI) stock increased by 337.79% to $42.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate
The FDA has granted Orphan Drug Designation to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) ADX-2191 (methotrexate for intravitreal injection) for primary... 
Via Benzinga
Exposures Product Safety
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma
From Aldeyra Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock moved upwards by 67.6% to $14.28 during Monday's pre-market session. The company's market cap stands at $684.2... 
Via Benzinga
Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics, And More
Insider buying can be an encouraging signal for investors, especially when markets are near all-time highs. Some insiders have taken advantage of initial public offerings. A few chief executive... 
Via Talk Markets
The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Once again, some insiders have taken advantage of initial... 
Via Benzinga
Aldeyra Therapeutics (ALDX) Q1 2021 Earnings Call Transcript
ALDX earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Galera Therapeutics (NASDAQ:GRTX) shares increased by 42.2% to $9.4 during Thursday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss Recent Business Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
60 Biggest Movers From Yesterday
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) shares gained 75.6% to settle at $43.73 on Wednesday. The company recently said it paid $1 million towards acquisition of... 
Via Benzinga
Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
From Aldeyra Therapeutics, Inc.
Via Business Wire
Why Aldeyra Therapeutics Stock Is Sinking Today
The company plans to conduct a public stock offering. 
Via The Motley Fool
41 Stocks Moving In Wednesday's Mid-Day Session
Gainers Aurora Mobile Limited (NASDAQ: JG) shares climbed 21.3% to $4.27 after Oppenheimer initiated coverage on the stock with an Outperform rating and a price target of $6 per... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Akari Therapeutics (NASDAQ:AKTX) stock moved upwards by 14.1% to $2.67 during Wednesday's pre-market session. The company's market cap stands at $102.7... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
25 Stocks Moving in Wednesday's Pre-Market Session
Gainers RiceBran Technologies (NASDAQ: RIBT) rose 16.1% to $1.37 in pre-market trading after jumping around 27% on Tuesday. The company is scheduled to report Q1 earnings today.... 
Via Benzinga
Aldeyra Seeks To Raise $125M Via Equity To Support Reproxalap US Application
Aldeyra Therapeutics Inc (NASDAQ: ALDX) intends to sell $125 million shares of its common stock in an underwritten public offering. Underwriters will... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) gained 51.2% to close at $24.90 on Tuesday. Urban Tea, Inc. (NASDAQ: MYT) rose 38.1% to settle at $4.64. Vaxart, Inc. (... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.